NoBACZ Healthcare, a spinout company from the University of Cambridge developing novel technologies to treat livestock wounds, has raised £4.8 million in a new funding round. While the company has primarily focused on veterinary healthcare solutions, it has said it is also exploring “human product" opportunities.
The investment will support the development and commercialisation of the firm’s “liquid bandage technology”. This patented system for treating wounds is said to be healthier and more effective than traditional methods.
The NoBACZ Healthcare team have said they explored how to solve dermatological diseases that are painful and costly to treat, leading to the creation of its signature liquid bandage. The bandage is a waterproof protective layer that can be applied as a spray, dip or gel.
According to the company, the system can seal away bacteria, drastically reducing the risk of wound infection that comes with the use of traditional bandages and wound dressings.
Dr Jonathan Powell, co-founder and chief executive of NoBACZ Healthcare, said: “We founded NoBACZ Healthcare with the goal of transforming healthcare solutions for a more sustainable future whilst reducing antibiotic use.”
“This new funding will fuel our expansion as we broaden our global product reach, launch our new range of products for the equine industry and continue to develop innovative veterinary healthcare solutions.”
The funding round was led by The Yield Lab, with additional participation from Adjuvo, ACF Investors, the University of Cambridge, The FSE Group, Parkwalk and Cambridge Enterprise Ventures.
Gentiane Gorlier, a general partner at The Yield Lab, commented: “The team has consistently impressed us with their vision, execution, and commitment to transforming animal healthcare with sustainable, antibiotic-free solutions.”
“Leading this round reflects our confidence in NoBACZ’s leadership and technology, and we believe the company is poised for significant global impact.”
